Aptose Biosciences Inc. (APS) Analysts See $-0.16 EPS

March 21, 2018 - By Maria Brooks

 Aptose Biosciences Inc. (APS) Analysts See $ 0.16 EPS

Analysts expect Aptose Biosciences Inc. (TSE:APS) to report $-0.16 EPS on March, 27 after the close.They anticipate $0.10 EPS change or 38.46 % from last quarter’s $-0.26 EPS. After having $-0.14 EPS previously, Aptose Biosciences Inc.’s analysts see 14.29 % EPS growth. The stock increased 4.24% or $0.2 during the last trading session, reaching $4.92. About 44,022 shares traded. Aptose Biosciences Inc. (TSE:APS) has 0.00% since March 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $144.17 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More news for Aptose Biosciences Inc. (TSE:APS) were recently published by: Globenewswire.com, which released: “Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase …” on March 07, 2018. Globenewswire.com‘s article titled: “Aptose to Present New CG’806 and APTO-253 Data at the 2018 AACR Annual Meeting” and published on March 15, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.